Morgan Stanley (NYSE:MS) upgraded Sartorius AG (ETR:SATG) (SRT3:GR) (OTC: SARTF), a prominent player in the bioprocessing industry, from Equalweight to Overweight, while also increasing the price ...

RBC Capital analyst Charles Weston maintained a Hold rating on Sartorius (0NIR – Research Report) today and set a price target of €275.00. The ...

(Reuters) - Shares in Sartorius jumped 15.6% on Tuesday after the Franco-German lab supplies maker's preliminary annual results beat expectations and despite a cautious outlook for 2025.

The life science group Sartorius today released its Annual Report for 2024. The document is available at the following link: Financial ...

RBC Capital analyst Charles Weston maintained a Buy rating on Sartorius Stedim Biotech (0RG8 – Research Report) today and set a price target of ...

Sartorius AG (OTCPK:SARTF) added ~13% in European trading on Tuesday, rallying the shares of its U.S. peers in the premarket after the German life sciences company posted preliminary financials ...

(RTTNews) - Sartorius Stedim Biotech reported preliminary fiscal 2024 net profit of 175.1 million euros, down 43.6% from last year. Earnings per share was 1.81 euros compared to 3.37 euros.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

In a challenging environment, Sartorius Stedim Biotech, a leading provider of innovative technologies for the manufacture of biologics, closed the fiscal year with a solid performance. With sales ...

Ladies and gentlemen, welcome to the Sartorius and Sartorius Stedim Biotech Conference Call on the Preliminary Results 2024 Conference Call and Live Webcast. I am Yousef, the Chorus Call operator.